Medical XpressAn off-the-shelf, dual-targeted CAR T-cell product shows promising results in preclinical studiesMedical Xpress"We aimed to overcome these challenges by demonstrating proof-of-concept for an off-the-shelf, dual-targeted CAR T-cell ap… Continue reading
CosmosLife 2.0: inside the synthetic biology revolutionCosmosImagine a future where synthetic jellyfish roam waterways looking for toxins to destroy, where eco-friendly plastics and fuels are harvested from vats of yeast, where viruses are programmed t… Continue reading
CosmosLife 2.0: inside the synthetic biology revolutionCosmosImagine a future where synthetic jellyfish roam waterways looking for toxins to destroy, where eco-friendly plastics and fuels are harvested from vats of yeast, where viruses are programmed t… Continue reading
CosmosSynthetic biology presents an ethical tightrope | CosmosCosmosSynthetic biology is a descendant of recombinant DNA (rDNA) technology, which transformed biology in the 1970s by allowing scientists to cut and paste DNA from one organism to another… Continue reading
CRISPRdisco Pipeline IDs, Annotates CRISPR Repeats, Cas Genes; Assembles Data in One RepositoryGenomeWebIndeed, barely a month ago, early-stage life sciences company Arbor Biotechnologies and the team of Patrick Hsu at the Salk Institute for Biological… Continue reading
GenomeWebBioinformatics Pipeline Annotates CRISPR Repeats, Cas Genes; Assembles Data in One RepositoryGenomeWebIndeed, barely a month ago, early-stage life sciences company Arbor Biotechnologies and the team of Patrick Hsu at the Salk Institute for Bio… Continue reading
Genetic Engineering & Biotechnology NewsSynthetic Nucleotides Improve CRISPR-Cas9 Specificity 10000-FoldGenetic Engineering & Biotechnology NewsScientists at the University of Alberta in Canada have developed a technology that can dramatically improve … Continue reading
|
DiaCarta, MIODx to Codevelop Diagnostic to Predict Immunotherapy Response
GenomeWeb NEW YORK (GenomeWeb) – DiaCarta and MIODx today said they plan to codevelop a diagnostic test to predict immunotherapy response based on MIODx’s immune sequencing technology, ClonoMap. The test will be developed and validated at DiaCarta’s CLIA … DiaCarta and MIODx Join Forces to Develop a Diagnostic Test to Predict Patient Responses to ImmunotherapyBusiness Wire (press release) |